UCI prostate cancer project awarded $1.2 million by state precision medicine initiative

November 15, 2016

Irvine, Calif., Nov. 15, 2016 -- University of California, Irvine health policy researchers have been awarded $1.2 million by the California Initiative to Advance Precision Medicine to develop more effective ways for prostate cancer patients and their physicians to customize treatment.

Dr. Sheldon Greenfield and Sherrie H. Kaplan, co-executive directors of UCI's Health Policy Research Institute, will lead the project. It was one of six funded today by the state initiative, which was created in 2015 to provide the infrastructure and resources necessary to advance precision medicine-oriented data, tools and applications in California.

"This grant represents an exciting opportunity to link patient-reported disease burden with tumor biomarkers to evaluate the effectiveness of prostate cancer treatment," said Greenfield, the Donald Bren Professor of Medicine at UCI. "We envision that study results will help doctors and patients tailor treatment based on a composite picture of the patient's illness, tumor biology and personal circumstances."

Prostate cancer is the most common cancer in men, with more than 200,000 new cases diagnosed each year in the U.S. It is the second-leading cause of cancer death in males and affects roughly 1 in 7 of them over their lifetime.

The project will focus on improving risk predictions, including both the benefits and the potential harms of different treatment strategies for early-stage prostate cancer. Among the most pressing challenges that face physicians who care for men with prostate cancer is evaluating one's potential benefit from treatment. As part of the two-year clinical study, prostate cancer patients will be given a detailed questionnaire that features 25 questions addressing myriad existing health issues to help determine the aggressiveness of treatment.

The final prognosis will be based on detailed patient characteristics, such as sociodemographic factors, health status and disease management burden, combined with traditional prostate cancer severity indicators and established genomic identifiers.

Greenfield expects that 600 patients from five Southern California-area hospitals will be enrolled. Along with the UCI personnel, the team - which has had considerable prior experience collaborating on research projects - will include investigators and patients from UCLA, Cedars-Sinai Medical Center, the Veterans Affairs Greater Los Angeles Healthcare System and the Veterans Affairs Long Beach Healthcare System.

"Right now, the evidence supports treatment decisions for the average patient. This study will give doctors much better data on which to base recommendations for individual patients," said Kaplan, adding that this approach will be applicable to other cancers and chronic diseases.

The six projects funded today by the California Initiative to Advance Precision Medicine aim to promote customized healthcare by using data-driven tools and analysis to develop new diagnostics, therapies and insights into disease. The winning teams will join forces to utilize data across research, clinical, environmental and population health settings to better diagnose, treat, manage and prevent disease.

Projects based at UC Davis, UC San Francisco, Children's Hospital Oakland Research Institute, Cedars-Sinai Medical Center and Sutter Health were also awarded grants.

The California Initiative to Advance Precision Medicine was launched by Gov. Jerry Brown last year and received additional funding in fiscal 2016-17. UC Health and UC San Francisco host the initiative with the Governor's Office of Planning & Research.
-end-
About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 30,000 students and offers 192 degree programs. It's located in one of the world's safest and most economically vibrant communities and is Orange County's second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit http://www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.

University of California - Irvine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.